07. June 2018
3D printing evolved as a promising technique to improve individualization of drug therapy. In particular, when printing sustained release solid dosage forms, as for instance implants, inserts, and also tablets, estimation of the drug release profile in vivo is necessary. In most cases, corresponding analyses cannot be performed at hospital or community pharmacies. Therefore, the present study aimed to develop a sustained release drug delivery system produced via 3D printing, which allows dose...
28. March 2018
Production of nanosuspension for drug bioavailability improvement has been accepted and frequently used in pharmaceutical industry. Normally, the preparation started from crystalline drug. However, some previous studies found that amorphous drug powder obtained from processes such as spray-drying might contribute to nanosizing process, i.e. reduced homogenization cycles and smaller achievable particle size. The mechanism behind this improved behavior was still unclear. In order to...
21. June 2017
Candesartan cilexetil is an ester prodrug antagonist to angiotensin II receptor type 1 (AT1) used in management of many cardiovascular diseases. The absolute bioavailability of candesartan cilexetil is about (14–40%). Therefore, the paper aim was to prepare and evaluate solid self-nanoemulsifying drug delivery systems for candesartan cilexetil in order to improve its solubility, dissolution and stability.
01. March 2016
Reports of drug shortages surfaced in news outlets in 2010. By 2011, the number of drug shortages peaked. Of the 251 problem drugs published by the FDA, 183 involved sterile injectable products (FDA/ CDER Drug Shortage Program). While many of the shortages were related to the inherent manufacturing complexity and daunting quality requirements of parenteral products, the FDA has cited delays in receiving raw materials and components from suppliers as a siginificant contributing factor. Many of...
22. February 2016
By Phil TaylorPhil Taylor, 22-Feb-2016 There are concerns that pharma companies are not fully prepared to meet the new requirements on risk-assessment for excipients, even though the deadline is just a few weeks away. More
24. August 2015
Low bioavailability nowadays often represents a challenge in oral dosage form development. Solid formulations composed of drug and phospholipid (PL), which, upon contact with water, eventually form multilamellar liposomes (i.e. ‘proliposomes’), are an emerging approach to solve such issue. Regarded as an ‘improved’ version of liposomes concerning storage stability, the potential and versatility of a range of such formulations for oral drug delivery have been extensively discussed....